5-panel vs 10-panel vs 12-panel drug test

The 5-panel test is the federal baseline. The Substance Abuse and Mental Health Services Administration (SAMHSA) defines a five-drug scope — marijuana metabolites (THC-COOH), cocaine metabolites, amphetamines (including methamphetamine), opiates, and phencyclidine (PCP) — that Department of Transportation–regulated employers must use under 49 CFR Part 40. If you operate commercial drivers, pilots, transit workers, or pipeline crews, this is the panel your program is required to run for pre-employment, random, post-accident, reasonable-suspicion, and return-to-duty testing.

Outside DOT regulation, the 5-panel is still the most common pre-employment screen for entry-level retail, hospitality, and light industrial roles because it is the cheapest test that still meets the federal definition of a drug screen. At Magenta's volume pricing, the per-test cost gap between a 5-panel and a 12-panel from the same product family is typically pennies, so the choice is rarely about budget alone — it is about scope.

Where the 5-panel falls short is anything beyond the SAMHSA-5. It does not detect benzodiazepines (alprazolam, diazepam, clonazepam), barbiturates, methadone, oxycodone, or buprenorphine. For a rehab center monitoring patient compliance, a pain clinic screening for prescription misuse, or a sober-living home where the relevant drugs of relapse are usually prescription opioids and benzodiazepines, the 5-panel will miss most of what you actually need to see. The same goes for forensic and probation contexts in many states.

If your program is governed by DOT or you need the absolute lowest unit cost for a basic compliance-only screen, the 5-panel is the right choice. For almost every other B2B use case, step up to a 10 or 12.

The 10-panel test layers five additional analytes on top of the SAMHSA-5. The most useful additions are benzodiazepines and methadone. Benzodiazepines (the alprazolam, diazepam, clonazepam, lorazepam family) are among the most commonly misused prescription drugs in the United States and are routinely missed by a 5-panel. Methadone is critical for any employer or program that needs to distinguish between licit opioid replacement therapy and illicit opioid use, since methadone is not detected by the standard opiate immunoassay.

The other three additions — barbiturates, methaqualone, and propoxyphene — are mostly legacy analytes. Barbiturates still appear in some pain management and veterinary diversion contexts but are far less common than they were 30 years ago. Methaqualone (Quaalude) has been off the U.S. market since the early 1980s. Propoxyphene (Darvon) was withdrawn by the FDA in 2010. Manufacturers keep them on the 10-panel because the immunoassay strips are inexpensive to include and the panel definition has not been updated; they rarely produce positives.

The 10-panel is the workhorse of non-DOT employer testing. It is the panel most third-party administrators default to for general pre-employment, post-incident, and random programs. Healthcare employers screening clinical staff, school districts running employee programs, and property managers conducting tenant screening all gravitate to the 10-panel because it covers the practical drugs of concern (the SAMHSA-5 plus benzos and methadone) without requiring the clinical justification that the 12-panel implies.

If you need a step up from the federal baseline but do not need expanded opioid coverage, the 10-panel is the right tool. If your program touches pain management, rehab, or sober living, skip to the 12.

The 12-panel test is the de facto clinical standard for any program where the relevant drugs of abuse extend beyond the SAMHSA-5 and beyond generic benzodiazepines. The two analytes that matter most on the upgrade from 10 to 12 are oxycodone and buprenorphine. Oxycodone (OxyContin, Percocet) is a semi-synthetic opioid that the standard opiate immunoassay does not reliably detect — without a dedicated oxycodone strip, an oxycodone-positive patient can show as opiate-negative. Buprenorphine (Suboxone, Subutex) is the most widely used medication for opioid use disorder, and a treatment program needs to be able to distinguish prescribed buprenorphine compliance from illicit opioid use.

Most 12-panel cups also add MDMA (ecstasy) as a separate analyte from amphetamines, which matters for college, residential treatment, and probation contexts where MDMA use is more prevalent than methamphetamine.

For rehab centers, the 12-panel is the baseline expectation. Inpatient and outpatient programs use it to monitor patient compliance with treatment plans, detect relapse early, and document chain of custody for insurance and accreditation. Sober-living homes use it as a condition of residency. Pain clinics use it to confirm that patients are taking prescribed opioids and not supplementing with illicit substances. Drug courts and probation officers use it because their populations frequently use the exact analytes the 12-panel adds.

One gap the 12-panel does not close on its own: fentanyl. The DEA continues to flag fentanyl as the leading driver of opioid overdose deaths, and the standard opiate immunoassay does not cross-react with fentanyl or its analogs. If your program is in any opioid-adjacent setting, pair your 12-panel cup with a dedicated fentanyl strip — either as a separate test or as a 13th analyte on a fentanyl-extended cup.